Merck KGaA (ETR: MRK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 60.83B |
| Revenue (ttm) | 20.96B |
| Net Income (ttm) | 2.70B |
| Shares Out | 434.78M |
| EPS (ttm) | 6.19 |
| PE Ratio | 22.60 |
| Forward PE | 14.80 |
| Dividend | 2.20 (1.57%) |
| Ex-Dividend Date | n/a |
| Volume | 130,917 |
| Open | 139.45 |
| Previous Close | 139.95 |
| Day's Range | 138.85 - 139.90 |
| 52-Week Range | 136.10 - 177.00 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 6, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Financial Performance
In 2023, Merck KGaA's revenue was 20.99 billion, a decrease of -5.57% compared to the previous year's 22.23 billion. Earnings were 2.82 billion, a decrease of -15.09%.
Financial StatementsNews
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
HUB internationally recognized pioneer in organoid development Acquisition expands MilliporeSigma’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potent...
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor RelationsBelen...
Merck KGaA 2024 Q3 - Results - Earnings Call Presentation
Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
Merck KGaA Non-GAAP EPS of €2.30, revenue of €5.27B; updates FY24 outlook
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and temporarily lower spending on drug research and development.
Merck KGaA Specifies Guidance Amid Soft Semiconductor Market
Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside positive growth trends in its other two businesses.
Merck KGaA, Darmstadt, Germany and Intel Launch Academic Research Program in Europe for More Sustainable Semiconductor Manufacturing
Following the announcement of the multidisciplinary research program last year, the selection process for funded projects has been completed Six projects involving eleven scientific institutions from ...
Merck KGaA: A Continued Long-Term Upside Despite Some Lag
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 was mixed-positive. Read more here.
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Shares of Charter Communications, Inc. (NASDAQ: CHTR) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter EPS and revenues. Charter Communications...
AI is driving semiconductor industry, says CEO Electronics at Merck KgaA
Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.
AI is driving semiconductor industry, says CEO Electronics at Merck KgaA
Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.
Why This Pharma Boss Isn’t Chasing the Obesity Hype
Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.
Merck KGaA Shares Jump on Expectations of AI Boost
The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.
Merck KGaA Shares Jump on Expectations of AI Boost
The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.
Merck KGaA Sees Post-Covid Life Sciences Rebound, Eyes M&A
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial setbacks and trimmed the top end of guidance for its life sciences unit.
MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA
Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building New rapid test offering with Blazar® CHO Animal Origin Free (AOF) delivers re...
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturing methods Utilizes Ultimus® Film for superior l...
Germany’s DAX 40 has a new female CEO: Daimler Truck appoints Karin Radstrom as next head in rare move
Radstrom will become just the second female CEO of a DAX 40 firm, joining Belen Garijo, the head of pharmaceutical giant Merck KGaA.
MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
New Pharmaceutical Auxiliary Materials cGMP standard introduced for cell culture media manufacturing Company first in the industry to receive EXCiPACT Certification Company’s cell culture media produc...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT064635...
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene...
Merck KGaA: The Drop Makes The Upside All The Sweeter
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark...
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating ...
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American ...